Loading clinical trials...
Loading clinical trials...
A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Conditions
Interventions
IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)
Paclitaxel
+3 more
Locations
7
United States
Advent Health
Orlando, Florida, United States
Washington University School of Medicine in St. Louis
St Louis, Missouri, United States
Providence Cancer Institute
Portland, Oregon, United States
Sanford Health
Sioux Falls, South Dakota, United States
Erlanger Health
Chattanooga, Tennessee, United States
Providence Sacred Heart Medical Center & Children's Hospital
Spokane, Washington, United States
Start Date
July 9, 2025
Primary Completion Date
October 31, 2032
Completion Date
October 31, 2032
Last Updated
April 13, 2026
NCT03050268
NCT06257264
NCT06964009
NCT00539162
NCT06710548
NCT05005403
Lead Sponsor
Imunon
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions